FDA Approves Novo Nordisk Wegovy Pill
Analysis based on 23 articles · First reported Dec 22, 2025 · Last updated Dec 23, 2025
The United States — Food and Drug Administration's approval of Novo Nordisk's Wegovy pill is expected to significantly expand the market for obesity treatments by offering a convenient oral option, potentially increasing Novo Nordisk's market share and putting pressure on Eli Lilly and Company to accelerate its own oral drug development. The availability of a pill form could also lead to lower costs, making these treatments more accessible and affordable for a broader patient demographic.
The United States — Food and Drug Administration has approved Novo Nordisk's Wegovy pill, making it the first daily oral medication for obesity. This approval gives Novo Nordisk a significant advantage over rival Eli Lilly and Company, whose oral drug, orforglipron, is still under review. The Wegovy pill contains semaglutide, the same active ingredient as the injectable Wegovy and Ozempic, and demonstrated similar weight loss efficacy in clinical trials. The new pill is expected to be available in the United States within weeks, with a starting dose priced at $149 per month. This development is anticipated to broaden access to obesity treatments, especially for patients hesitant about injections, and potentially reduce overall costs, impacting the 100 million Americans affected by obesity. The approval was welcomed by organizations like the Obesity Care Advocacy Network, and follows previous efforts by the Donald Trump administration to negotiate lower drug prices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard